Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Summary

The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia

Timeline

Start

2021-02-15

Primary completion

2021-05-17

Completion

2021-06-30

Outcome

Met primary endpoint

release “the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary” opusgtx.com ↗

release “VEGA-1 Phase 2 trial of Nyxol plus low-dose pilocarpine (LDP) for the treatment of presbyopia; the trial met its primary endpoint” opusgtx.com ↗

release “A Phase 2 and the first Phase 3 trial for the use of Phentolamine Ophthalmic Solution 0.75% to treat presbyopia met their primary endpoints.” opusgtx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Phentolamine	Small molecule	0.75 %	Other
Subject	Pilocarpine	Unknown	—	Other

Indications